Regional Lymph Node Basin (RLNB) Relapse after Adjuvant Ipilimumab (Ipi) Anti-CTLA4 Immunotherapy in Stage III Melanoma: A Subgroup Analysis of a Randomized Placebo-Controlled Trial
Christopher A. Barker(Cornell University), Jedd D. Wolchok(Cornell University), Douglas B. Johnson(Vanderbilt University Medical Center), Jonathan D. Schoenfeld(Brigham and Women's Hospital), F. Stephen Hodi(Harvard University), J.J. Caudell(Moffitt Cancer Center), K.A. Ahmed(Moffitt Cancer Center)
International Journal of Radiation Oncology*Biology*Physics
September 23, 2017
Cited by 1
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k